抄録
Functional dyspepsia (FD) is a highly prevalent condition with major socioeconomic and healthcare impact. To date, no pharmacological treatment for FD has been approved. The Rome consensus proposed to subdivide FD into postprandial distress syndrome (PDS), characterized by meal-related symptoms and epigastric pain syndrome, characterized by pain and burning. Acotiamide (Z-338 or YM443) is a new drug, developed for the treatment of FD. Acotiamide enhances acetylcholine release from enteric neurons through muscarinic receptor antagonism and acetycholinesterase inhibition, thereby enhancing gastric emptying and gastric accommodation. Acotiamide was evaluated in FD in clinical studies in Europe, Japan and the USA, beneficial effects were observed for the PDS symptoms of postprandial fullness and early satiation, with a dose of 100 mg three-times a day. A 4-week placebo-controlled Phase III study in PDS patients in Japan confirmed efficacy of acotiamide in relieving postprandial fullness, early satiation and upper abdominal bloating.
| 元の言語 | English |
|---|---|
| ページ（範囲） | 533-544 |
| ページ数 | 12 |
| ジャーナル | Expert Review of Gastroenterology and Hepatology |
| 巻 | 6 |
| 発行部数 | 5 |
| DOI | |
| 出版物ステータス | Published - 2012 9 |
| 外部発表 | Yes |
Fingerprint
ASJC Scopus subject areas
- Hepatology
- Gastroenterology
これを引用
Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia : Postprandial distress syndrome. / Altan, Ege; Masaoka, Tatsuhiro; Farré, Ricard; Tack, Jan.
：: Expert Review of Gastroenterology and Hepatology, 巻 6, 番号 5, 09.2012, p. 533-544.研究成果: Article
}
TY - JOUR
T1 - Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia
T2 - Postprandial distress syndrome
AU - Altan, Ege
AU - Masaoka, Tatsuhiro
AU - Farré, Ricard
AU - Tack, Jan
PY - 2012/9
Y1 - 2012/9
N2 - Functional dyspepsia (FD) is a highly prevalent condition with major socioeconomic and healthcare impact. To date, no pharmacological treatment for FD has been approved. The Rome consensus proposed to subdivide FD into postprandial distress syndrome (PDS), characterized by meal-related symptoms and epigastric pain syndrome, characterized by pain and burning. Acotiamide (Z-338 or YM443) is a new drug, developed for the treatment of FD. Acotiamide enhances acetylcholine release from enteric neurons through muscarinic receptor antagonism and acetycholinesterase inhibition, thereby enhancing gastric emptying and gastric accommodation. Acotiamide was evaluated in FD in clinical studies in Europe, Japan and the USA, beneficial effects were observed for the PDS symptoms of postprandial fullness and early satiation, with a dose of 100 mg three-times a day. A 4-week placebo-controlled Phase III study in PDS patients in Japan confirmed efficacy of acotiamide in relieving postprandial fullness, early satiation and upper abdominal bloating.
AB - Functional dyspepsia (FD) is a highly prevalent condition with major socioeconomic and healthcare impact. To date, no pharmacological treatment for FD has been approved. The Rome consensus proposed to subdivide FD into postprandial distress syndrome (PDS), characterized by meal-related symptoms and epigastric pain syndrome, characterized by pain and burning. Acotiamide (Z-338 or YM443) is a new drug, developed for the treatment of FD. Acotiamide enhances acetylcholine release from enteric neurons through muscarinic receptor antagonism and acetycholinesterase inhibition, thereby enhancing gastric emptying and gastric accommodation. Acotiamide was evaluated in FD in clinical studies in Europe, Japan and the USA, beneficial effects were observed for the PDS symptoms of postprandial fullness and early satiation, with a dose of 100 mg three-times a day. A 4-week placebo-controlled Phase III study in PDS patients in Japan confirmed efficacy of acotiamide in relieving postprandial fullness, early satiation and upper abdominal bloating.
KW - acotiamide
KW - early satiation
KW - functional dyspepsia
KW - gastric accommodation
KW - gastric emptying
KW - postprandial fullness
KW - randomized-controlled trial
UR - http://www.scopus.com/inward/record.url?scp=84867551602&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867551602&partnerID=8YFLogxK
U2 - 10.1586/egh.12.34
DO - 10.1586/egh.12.34
M3 - Article
C2 - 23061703
AN - SCOPUS:84867551602
VL - 6
SP - 533
EP - 544
JO - Expert Review of Gastroenterology and Hepatology
JF - Expert Review of Gastroenterology and Hepatology
SN - 1747-4124
IS - 5
ER -